307 related articles for article (PubMed ID: 31076446)
21. [Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of
Tang SH; Lu Y; Zhang PS; Chen D; Liu XH; DU XH; Cao JJ; Li SY; Sha KY; Chen LG; Zhuang XX; Ye PP; Lin L; Pei RZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):45-49. PubMed ID: 36765475
[TBL] [Abstract][Full Text] [Related]
22. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
23. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
[TBL] [Abstract][Full Text] [Related]
24. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
25. FLT3-ITD-associated gene-expression signatures in NPM1-mutated cytogenetically normal acute myeloid leukemia.
Huang L; Zhou K; Yang Y; Shang Z; Wang J; Wang D; Wang N; Xu D; Zhou J
Int J Hematol; 2012 Aug; 96(2):234-40. PubMed ID: 22688855
[TBL] [Abstract][Full Text] [Related]
26. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
27. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
28. Significance of NPM1 Gene Mutations in AML.
Hindley A; Catherwood MA; McMullin MF; Mills KI
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576201
[TBL] [Abstract][Full Text] [Related]
29. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
31. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
32. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
33. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
[TBL] [Abstract][Full Text] [Related]
34. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
35. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
[TBL] [Abstract][Full Text] [Related]
36. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
38. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
[TBL] [Abstract][Full Text] [Related]
39. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
40. CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.
Tang L; Huang H; Tang Y; Li Q; Wang J; Li D; Zhong Z; Zou P; You Y; Cao Y; Kong Y; Guo A; Zhou S; Li H; Meng F; Xiao Y; Zhu X
Clin Transl Med; 2022 Sep; 12(9):e1043. PubMed ID: 36163632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
